Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 4.52 million shares due to the exercise of options on November 11, 2025 [1] Company Summary - The company will issue 4.52 million shares as a result of option exercises [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股 ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 4.055 million ordinary shares on November 10, 2025, as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - Share Issuance - The company issued 4.055 million ordinary shares as part of the option exercise [1] - Historical Context - The share option plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1] - Future Implications - The exercise of options may impact the company's capital structure and shareholder equity [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 4.055 million ordinary shares on November 10, 2025, as part of the exercise of options under its pre-IPO share option plan adopted on January 5, 2016, and revised on August 10, 2016 [1] Summary by Category - **Company Actions** - The company is exercising options that will result in the issuance of 4.055 million ordinary shares [1]

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的 ...

Group 1 - The Hong Kong stock market saw significant gains on November 10, with the Hang Seng Index rising by 1.55% to close at 26,649.06 points, the Hang Seng Tech Index increasing by 1.34% to 5,915.56 points, and the National Enterprises Index up by 1.90% to 9,443.24 points [1] - The Hang Seng Index opened at 26,319.40 points, fluctuated around this level in the morning, and surged in the afternoon, ultimately gaining 407.23 points with a total turnover exceeding 214.7 billion HKD [1] - The southbound trading under the Stock Connect saw a net inflow of over 6.6 billion HKD on the same day [1] Group 2 - Most sectors experienced upward movement, including biopharmaceuticals, technology, real estate, gold, banking, insurance, brokerage, and new consumption, while sectors like coal, lithium batteries, and building materials showed mixed results, and chips and electricity sectors mostly declined [1] - Notable individual stock performances included Pop Mart rising by 8.11%, China Resources Land increasing by 4.45%, BYD gaining 3.98%, and Ideal Auto up by 2.39%, while SMIC fell by 0.99% [1] - Among the top three stocks by trading volume, Tencent Holdings rose by 2.44% with a turnover exceeding 9.3 billion HKD, Alibaba increased by 2.06% also with over 9.3 billion HKD in turnover, and Xiaomi Group saw a slight increase of 0.28% with a turnover exceeding 6.9 billion HKD [2]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 3.51 million shares on November 7, 2025, due to the exercise of options [1] Company Summary - The company will issue 3.51 million shares as a result of option exercises [1]

Core Viewpoint - WuXi Biologics (02269) announced the issuance of a total of 3.51 million shares on November 7, 2025, due to the exercise of options [1] Company Summary - The company is set to issue 3.51 million shares as a result of option exercises [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Core Viewpoint - WuXi Biologics (02269) announced the issuance of 6 million ordinary shares on November 6, 2025, as part of the stock option plan adopted prior to its initial public offering in January 2016, which was revised on August 10, 2016 [1] Summary by Category - **Company Actions** - The company will issue 6 million ordinary shares as part of the stock option plan [1] - **Timeline** - The issuance is scheduled for November 6, 2025 [1] - **Plan Details** - The stock option plan was initially adopted on January 5, 2016, and revised on August 10, 2016 [1]